Earnings dates and session timing shown here are aggregated from third-party sources, are frequently estimated, and are subject to change or confirmation by the reporting company. Nothing on this site is financial advice.
OmniAb Inc. is an innovative biotechnology company dedicated to the development of fully human therapeutic antibodies via its advanced OmniAb platform. This proprietary technology enables the rapid identification and optimization of effective therapies across various disease areas, thereby enhancing the likelihood of successful clinical outcomes. By establishing strategic partnerships and collaborations, OmniAb streamlines its drug development processes and improves access to groundbreaking treatments. Supported by a seasoned leadership team and a robust pipeline of product candidates, the company is strategically positioned to capitalize on the growing opportunities within the biopharmaceutical industry.
Quotes and fundamental data are delayed and provided for informational purposes only — nothing on this page is financial advice. Figures are as reported by the company and its data providers and may be revised. Estimates reflect analyst consensus at the time of each report.
$4.07
| Quarter | EPS | Revenue | Price move | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Est | Adj | Result | GAAP | Est | Actual | Surprise | 1D Pre | On-Day | 1D Post | |
Q ended Jun 30, 2026 Reported Aug 6, 2026 | $-0.11 | $-0.05 | Beat +54.5% | $-0.05 | $4.69M | $13.41M | +185.9% | 1D Pre+1.5% | On-Day+10.3% | 1D Post+37.5% |
Q ended Mar 31, 2026 Reported May 7, 2026 | $-0.10 | $-0.06 | Beat +40.0% | $-0.06 | $5.6M | $14.4M | +157.1% | 1D Pre+2.1% | On-Day+2.8% | 1D Post+12.9% |
Q ended Dec 31, 2025 Reported Mar 4, 2026 | $-0.08 | $-0.11 | ||||||||
Dashed outlines show the analyst consensus estimate for periods where one was published. Hover or tap a bar for exact figures. Values as reported; not adjusted for splits after the report date.
| — |
| $9M |
| $8.38M |
| -6.9% |
| 1D Pre-1.7% |
| On-Day+4.6% |
| 1D Post+10.5% |
Q ended Sep 30, 2025 Reported Nov 4, 2025 | $-0.13 | $-0.14 | Miss -7.7% | — | $5.64M | $2.24M | -60.3% | 1D Pre-4.5% | On-Day0.0% | 1D Post-3.7% |